Larry Greller, formerly assistant director of bioinformatics mathematical biology at SmithKline Beecham Pharmaceuticals, has been named director of mathematical biology and systems modeling at Molecular Mining of Kingston, Ontario.
Greller received his PhD in mathematical molecular biology from the University of Pennsylvania, an MS in computer and information science from Penn’s Moore School of Electrical Engineering, and a BS in Physics from Drexel University.
NeoTherapeutics has hired Frank Chiu as director, biostatistics and data management.
Chiu will direct efficacy and safety analyses for the company’s upcoming clinical studies of Neotrofin in Alzheimer’s disease, Parkinson’s disease, and spinal cord injury. He will also manage data and develop statistical analysis plans for regulatory filings.
Previously, Chiu held a number of positions in biostatistics and data management at Ligand Pharmaceuticals and Allergan. He has been involved in data management and statistical analysis for two drugs that were approved by the US FDA and are now on the market.
Odyssey Pharmaceuticals has appointed Anthony Carrano as acting director of research.
In his previous post as associate director of Lawrence Livermore National Laboratory, Carrano spearheaded the Human Genome Project for the Department of Energy. Under his direction, the Human Genome Center built a detailed physical map for chromosome 19, discovered numerous genes linked to human diseases, and established programs in functional genomics and computational biology to integrate structural, bioinformatics, and biochemical methods to understand protein function.
Carrano was president of the Human Genome Organization Americas from 1996 to 1999 and a US trustee of HUGO from 1994 to 2000.